Bone Mineral Disease After Kidney Transplantation

Area of Science:

• Nephrology
• Endocrinology
• Orthopedics

Background:

• Chronic kidney disease-mineral bone disorder (CKD-MBD) persists post-kidney transplantation, stemming from pre-existing issues and new alterations.
• This leads to mineral metabolism abnormalities like hypercalcemia and hypophosphatemia, alongside bone issues such as low bone mineral density and fractures.

Purpose of the Study:

• To review the multifaceted nature of CKD-MBD post-kidney transplantation.
• To identify key factors contributing to mineral and bone abnormalities and elevated fracture risk.
• To outline current and potential treatment strategies for managing CKD-MBD in transplant recipients.

Main Methods:

• Literature review and synthesis of existing evidence on CKD-MBD post-transplantation.
• Analysis of pathogenic mechanisms, risk factors, and clinical consequences.
• Evaluation of therapeutic interventions for mineral and bone disorders.

Main Results:

• Post-transplant hypercalcemia often results from persistent secondary hyperparathyroidism; hypophosphatemia is linked to high PTH and FGF23 levels.
• Low bone turnover is the most common bone alteration, though high-turnover disease also occurs.
• Fracture risk is significantly elevated (four-fold) in transplant patients due to factors like diabetes, age, and steroid use.

Conclusions:

• CKD-MBD post-transplantation is complex, influenced by immunosuppression, PTH, vitamin D, and phosphate levels.
• Effective management requires addressing mineral metabolism, bone health, and fracture risk factors.
• Preventing, minimizing, diagnosing, and treating CKD-MBD is vital for reducing morbidity and mortality in kidney transplant recipients.